The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial

Francesco Fioretti(Baylor Scott & White Health), Carla Cristina Vicente, Stefano Corda(Université Paris Cité), Javed Butler(Jackson Memorial Hospital), Gemma Macdonald, Christopher Adlbrecht, Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), SCOTT McKENZIE, Marcia López, MARISA VICO, Carolyn S.P. Lam(University of Glasgow), Inga Bayh(Fresenius Medical Care (Germany)), M Mirna, Irina Barash(Merck & Co., Inc., Rahway, NJ, USA (United States)), Diego Arakaki, Alicia Chan, Ezequiel Vottero, Kristen Kopp, M-C Leitgeb, Martín Suárez, Angela Romero Zarante, Carmine De Pasquale, Miguel Hominal, Yenisca Zambrano, Diego Aizenberg, Santiago Coussio, Viktoria Rausch, Natalya Beer, Erica Giozzi, Andreas Schober, Brendan McQuillan, Aiwen Xing(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher M O’Connor(Alaska Heart and Vascular Institute), Manuela Rossmaier, Miriam Gelersztein, for the VICTOR Study Group, Oscar Montaña, Kathryn Stibilj, John Atherton, Robert J Mentz(Clinical Research Institute), Justin A Ezekowitz(University of Alberta), Johann Auer, David Colquhoun, Lydia Lilwall, Jose Saraiva, Cordula Koehler, Gloria Cendali, Simeoni Thomas, Denise Healy, Dirk von Lewinski(Medical University of Graz)
European Journal of Heart Failure
March 20, 2026
Cited by 1


Related Papers